1.
2.
Leukemia
; 31(4): 991-994, 2017 04.
Article
in English
| MEDLINE
| ID: mdl-28025580
Subject(s)
Basigin/genetics , Carrier Proteins/genetics , Gene Expression/genetics , Membrane Proteins/genetics , Multiple Myeloma/genetics , Thyroid Hormones/genetics , Biomarkers, Tumor/genetics , Cell Membrane/genetics , Glycolysis/genetics , Humans , Macrophages , Multiple Myeloma/pathology , Plasma Cells/pathology , Prognosis , Thyroid Hormone-Binding Proteins
3.
Blood Cancer J
; 6: e397, 2016 Feb 26.
Article
in English
| MEDLINE
| ID: mdl-26918361
ABSTRACT
We employed a customized Multiple Myeloma (MM)-specific Mutation Panel (M(3)P) to screen a homogenous cohort of 142 untreated MM patients for relevant mutations in a selection of disease-specific genes. M(3)Pv2.0 includes 77 genes selected for being either actionable targets, potentially related to drug-response or part of known key pathways in MM biology. We identified mutations in potentially actionable genes in 49% of patients and provided prognostic evidence of STAT3 mutations. This panel may serve as a practical alternative to more comprehensive sequencing approaches, providing genomic information in a timely and cost-effective manner, thus allowing clinically oriented variant screening in MM.